San Francisco, California, United States, September 2025 — Corleen Roche has been appointed as Chief Financial Officer at Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a pioneering leader in tumor infiltrating lymphocyte (TIL) cell therapies for cancer treatment. In her new role, she will oversee financial strategy, operations, and planning as the company advances its commercial launch and strengthens its leadership in cell therapy innovation.
Most recently, Corleen served as Chief Financial Officer at CG Oncology, where she led financial operations and strategic initiatives to support growth in the oncology sector.
Before that, she was Chief Financial Officer at Immunome, Inc., contributing to financial leadership in the biotech space with a focus on innovative immunotherapies.
Earlier in her career, Corleen held senior leadership roles including US CFO at Biogen, where she managed financial operations for the company’s largest commercial unit, and CFO Biopharma NA at Sandoz, a division of Novartis, where she supported the launch of breakthrough biosimilars.
She also gained extensive leadership experience through financial leadership positions at ioGenetics, Corporate Financial Advisors, Wyeth (now Pfizer), CSL Behring, Auxilium Pharmaceuticals, Sanofi, and PwC, where she began her career. With more than three decades of expertise, Corleen brings a proven record of driving financial excellence across global biopharmaceutical and biotechnology organizations.
About Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) is dedicated to pioneering a transformational approach to curing cancer through tumor infiltrating lymphocyte (TIL) therapies. By harnessing the human immune system’s ability to recognize and destroy diverse cancer cells, the Iovance TIL platform has shown promising clinical outcomes across multiple solid tumors. Headquartered in the San Francisco Bay Area, Iovance operates its state-of-the-art Iovance Cell Therapy Center (iCTC) in Philadelphia, with additional research facilities in Tampa, Florida. The company is advancing commercial launches, expanding R&D, and building robust internal manufacturing capabilities to extend and improve the lives of patients worldwide.
Read Also : When HR “Produces Nothing”: A Response to Jennifer Sey’s Anti-HR Vision
The Fine Balance: Navigating Work, Life, and Mental Wellbeing
Mind the Leadership Gap – From Learning to Real-World Impact
How the Adecco Group is empowering its employees for the future of work
